Axial spondyloarthritis, psoriatic arthritis and systemic lupus erythematosus share common molecular features based on post-hoc analysis of serum biomarkers
Authors:
- Rikke MalmkvistRMRikke Malmkvist
- Anne-Christine Bay-JensenABAnne-Christine Bay-Jensen
- Dovile SinkeviciuteDSDovile Sinkeviciute
- Signe Holm NielsenSigne Holm Nielsen
- Monica Toft HannaniMHMonica Toft Hannani
- Peder FrederiksenPFPeder Frederiksen
- Morten Asser KarsdalMKMorten Asser Karsdal
- Sheng GaoSGSheng Gao
- Warner ChenWCWarner Chen
Open Access
- 30 October 2025
- journal article
- cohort studies
- Published by Springer Nature in Rheumatology International
- Vol. 45 (11) , 1-12
Abstract
Axial spondyloarthritis (axSpA), psoriatic arthritis (PsA), and systemic lupus erythematosus (SLE) are distinct rheumatological diseases with common molecular features. This study explored tissue-associated remodelling endotypes using blood-based biomarkers reflecting interstitial matrix and basement membrane remodelling. Baseline serum samples from radiographic axSpA (r-axSpA) (NCT02437162/NCT02438787) ( n = 66), PsA (NCT03158285) ( n = 267) and SLE (NCT02349061) ( n = 97) studies were analysed alongside healthy donors. Biomarkers of collagen turnover (C1M, C2M, C3M, C4M, C6M, C10C, PRO-C1, PRO-C2, PRO-C3, PRO-C4, PRO-C6) were measured by immunoassays and compared using Kruskal-Wallis tests. K-means clustering ( k = 3) of r-axSpA, PsA and SLE patients was applied to construct disease endotype clusters. Serum C1M, C3M, C4M, C6M, and PRO-C3 markers were elevated up to 4.2-fold ( p p < 0.001) in PsA and SLE patients versus healthy donors. PsA and r-axSpA patients showed increased levels of serum PRO-C2, PRO-C4, and PRO-C6 up to 1.4-fold ( p < 0.025) versus healthy donors. Three endotypes were identified: 1) hypertrophic ( n = 171), with elevated C10C, low PRO-C4 and lower disease activity reflected by CRP, ASDAS (r-axSpA), PASI, DAS28 (PsA) and joint scores (SLE); 2) fibrolytic ( n = 156), with high tissue degradation, increased PRO-C4 and severe inflammation with elevated disease activity; 3) fibrogenic ( n = 93), with increased cartilage degradation (C2M), fibrosis (PRO-C3, PRO-C6) and moderate disease activity. Tissue-associated remodelling profiles highlight heterogeneity within each disease and common molecular features, revealing clinically relevant subgroups. Identifying biomarker endotypes may guide targeted treatments and inform drug repurposing across rheumatological diseases.Keywords
Funding Information
- Københavns Universitet
This publication has 45 references indexed in Scilit:
- Collagen Turnover Biomarkers Associate with Active Psoriatic Arthritis and Decrease with Guselkumab Treatment in a Phase 3 Clinical Trial (DISCOVER-2)Rheumatology and Therapy, 2022
- Profiling and targeting connective tissue remodeling in autoimmunity - A novel paradigm for diagnosing and treating chronic diseasesAutoimmunity Reviews, 2021
- Potential diagnostic value of a type X collagen neo-epitope biomarker for knee osteoarthritisOsteoarthritis and Cartilage, 2019
- Three Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Studies Evaluating the Efficacy and Safety of Ustekinumab in Axial SpondyloarthritisArthritis & Rheumatology, 2018
- Diagnosis and Management of Rheumatoid ArthritisJAMA, 2018
- Translational Biomarkers and Ex Vivo Models of Joint Tissues as a Tool for Drug Development in Rheumatoid ArthritisArthritis & Rheumatology, 2018
- Ankylosing spondylitis is characterized by an increased turnover of several different metalloproteinase-derived collagen species: a cross-sectional studyRheumatology International, 2011
- Application of biomarkers in the development of drugs intended for the treatment of osteoarthritisOsteoarthritis and Cartilage, 2011
- Enzyme-linked immunosorbent assay (ELISAs) for metalloproteinase derived type II collagen neoepitope, CIIM—Increased serum CIIM in subjects with severe radiographic osteoarthritisClinical Biochemistry, 2011
- Enzyme-linked immunosorbent serum assays (ELISAs) for rat and human N-terminal pro-peptide of collagen type I (PINP) — Assessment of corresponding epitopesClinical Biochemistry, 2010